EGFR L718Q mutation occurs without T790M mutation in a lung adenocarcinoma patient with acquired resistance to osimertinib

Antzeko izenburuak

• Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
  nork: Song, Yang, et al.
  Argitaratua: (2020)
• Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
  nork: Zheng, Lin-Peng, et al.
  Argitaratua: (2018)
• Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
  nork: Sakai, Hitomi, et al.
  Argitaratua: (2017)
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
  nork: Bean, James, et al.
  Argitaratua: (2007)
• Successful osimertinib treatment in a patient who exhibited intramedullary spinal cord metastases of lung adenocarcinoma with an acquired EGFR T790M mutation
  nork: Horiuchi, Kohei, et al.
  Argitaratua: (2019)